Teresa Klinowska
AstraZeneca (United Kingdom)(GB)AstraZeneca (Singapore)(SG)AstraZeneca (Poland)(PL)AstraZeneca (Spain)(ES)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Estrogen and related hormone effects, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer(2014)2,182 cited
- → Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor(2014)591 cited
- → AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family(2012)497 cited
- → Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor(2016)473 cited
- → Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)(2013)258 cited
- → Laminin and β1 Integrins Are Crucial for Normal Mammary Gland Development in the Mouse(1999)136 cited